Pemziviptadil (PB1046) — clinical trials using this drug

Public-registry trials using Pemziviptadil (PB1046) that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.

Trial	Sponsor	Condition	Phase	Sites
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).	PhaseBio Pharmaceuticals Inc.	Acute Respiratory Distress Syndrome	PHASE2	4

Free site-risk snapshot for any of these trials

Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →